Martin Shkreli

Immediately avoid or short Capricor Therapeutics (CAPR) due to severe regulatory scrutiny and devastating FDA briefing documents regarding data manipulation. Capitalize on the recent semiconductor sell-off by aggressively buying NVIDIA (NVDA) on market weakness as a long-term growth play targeting its path toward a $10 trillion valuation. Look for value-buying opportunities in Micron Technology (MU) during sharp market pullbacks to capitalize on fundamentally constrained memory supply chains. Exercise extreme caution with speculative quantum computing stocks like D-Wave (QBTS), IonQ (IONQ), and Rigetti (RGTI), considering short positions on overhyped rallies driven by empty press releases. Add Tyra Biosciences (TYRA) to your watchlist ahead of crucial clinical trial data catalysts scheduled for the first and second halves of the year.

Accumulate shares of Intel (INTC) during post-earnings volatility, as the market is offering a strong long-term buying opportunity despite solid fundamentals. Treat recent weakness in mega-cap leaders like Alphabet (GOOGL) as an attractive accumulation phase for patient, long-term investors. Capitalize on high-volume intraday momentum shifts in memory plays like Micron Technology (MU), while preparing for extreme volatility and beta. Avoid volatile consumer health stocks like Hims & Hers Health (HIMS) due to growing market skepticism surrounding peripheral peptide product expansions. Maintain a cautious stance on Broadcom (AVGO) as a potential short candidate due to emerging competitive threats from rivals taking custom silicon market share.

Consider buying the dip on Alphabet (GOOGL) to capitalize on the post-earnings sell-off, as high capital expenditure concerns are likely a temporary overreaction. Target Micron Technology (MU) as a powerful semiconductor momentum play while it approaches the critical $1,000 price milestone. Exercise caution and avoid rushing into Tesla (TSLA) given its sharp 8% to 14% drop, negative free cash flow, and margin compression. Monitor ServiceNow (NOW) for stabilization after volatile post-earnings price action filled its gap in a difficult macro environment for software stocks. Finally, investigate Thermo Fisher Scientific (TMO) for potential short setups if its aggressive 6% to 9% rally proves to be fundamentally unsupported.

Buy the dip on Alphabet Inc. (GOOG / GOOGL) as surging cloud revenues and massive AI infrastructure demand outweigh near-term negative free cash flow. Target a near-term price of $1,000 to $1,100 for Micron Technology (MU) as booming AI data center memory demand drives the stock higher from current levels. Utilize Super Micro Computer (SMCI) trading around $31 to $32 as a high-beta proxy to capture short-term momentum from hyperscale AI server deployments. Accumulate Arrowhead Pharmaceuticals (ARWR) in the $88 to $93 range as a strong long opportunity following recent positive clinical trial data. Treat Cerebras Systems (CBRS) as a strictly tactical trading vehicle given its extreme intraday volatility and poor profit margins near the $200–$220 range.

Buy Adobe (ADBE) on pullbacks after its Morgan Stanley downgrade dip, as the sell-off is seen as overdone.
Short Danaher (DHR) following its 14% post-earnings drop, as weak growth and a messy acquisition story suggest further downside.
Accumulate Apple (AAPL) on dips, with recent large purchases around $227 indicating high conviction.
Consider Biohaven (BHVN) for a pre-catalyst trade ahead of upcoming clinical readouts, but size for binary risk.
Active traders can scalp Micron (MU) swings around the $932 level, though rallies may quickly fade.

Investors should maintain long positions in Micron (MU) and NVIDIA (NVDA), as rising memory prices and high demand from price-insensitive cloud providers continue to drive the semiconductor sector. Clinical data catalysts are approaching for 10x Genomics (TXG) and Scion (SION), though these remain high-risk "binary" events that will cause significant price swings this summer. For those seeking a contrarian software play, Adobe (ADBE) is reaching an attractive entry point after recent weakness, while Microsoft (MSFT) remains the preferred core holding for stable tech exposure. Active traders should look to short Bloom Energy (BE) due to its high valuation and persistent price "bleeding," or Hut 8 (HUT) following its recent news-driven spike. Monitor AMD closely for official confirmation on GPU shipping dates to verify if rumored production delays are impacting the stock's timeline.

Investors should consider Micron Technology (MU) as a high-conviction "buy the dip" opportunity, with potential earnings reaching $34-$43 per share by 2027 as it challenges NVIDIA (NVDA) for net income dominance. While the broader semiconductor sector has faced technical liquidations, Hynix remains a recommended safe haven for those seeking direct exposure to High Bandwidth Memory. Avoid Intuitive Surgical (ISRG) and Abbott Laboratories (ABT) at current levels, as their valuations remain unattractive despite recent price drops. In the biotech space, exercise extreme caution with 10x Genomics (TXG) ahead of its August Phase 3 data, as the options market is currently pricing in a high probability of failure. For long-term growth, prioritize major tech leaders like Apple, Amazon, and Alphabet following recent market volatility, as fundamental value is expected to prevail over temporary price dips.

Despite the current semiconductor sell-off, Micron (MU) and SK Hynix remain high-conviction long-term plays in the memory sector, though investors should wait for Google and Meta earnings to confirm continued AI infrastructure spending. Ultragenix (RARE) is highlighted as a top-tier long opportunity with the potential to double in value if its Sanfilippo drug is approved and Phase 3 Angelman Syndrome data succeeds later this year. PayPal (PYPL) is positioned as a strategic acquisition target, with expectations that the company will be sold to a larger bidder like SpaceX within the next 12 months. For speculative biotech traders, Tenax Therapeutics (TENX) offers a high-risk binary event ahead of its Levosimendan trial data expected by late August. Conversely, investors should consider shorting Oklo (OKLO) and Lucid (LCID), while avoiding Apple (AAPL) at its current valuation.

Avoid buying the dip in IBM following its negative earnings pre-announcement, as it signals a broader contraction in corporate IT spending that could weigh on the entire tech sector. Consider a short position on Bristol Myers Squibb (BMY) due to a failing product pipeline and looming revenue cliffs for its core franchises. Take a bearish stance on Micron (MU) and the memory sector, as the IBM news suggests cyclical risks for hardware spending are being underestimated. For a high-conviction long opportunity, look to Alnylam (ALNY), which is currently viewed as significantly undervalued. Conversely, look for a contrarian entry point in Adobe (ADBE) on its recent weakness, as its fundamental business model remains stronger than enterprise peers like IBM.

Consider Q32 Bio (Q32) as a high-conviction long-term play following positive Phase II results for Benpigabart, a biologic for Alopecia Areata that lacks the "Black Box" safety warnings of current JAK inhibitors. With a registration-directed Phase III program slated for early 2027, the drug aims to capture a $5 billion market by offering a safer, more durable alternative to Olumiant and Litfulo. Conversely, maintain a bearish outlook on Agenus (AGEN), viewing recent price spikes as a "dead cat bounce" and targeting a return to the $3.00–$3.50 range. In the semiconductor space, exercise caution with Micron (MU) and Western Digital (WDC), as high capital expenditures and crowded positioning may limit near-term upside despite AI demand. Finally, remain skeptical of Bitcoin (BTC) and the broader memory trade, focusing instead on free cash flow over earnings per share to navigate current market volatility.

The semiconductor sector is currently experiencing a "crowded trade" sell-off, creating a potential value entry for SanDisk which is now down 50% from its peak. Investors should consider rotating capital out of hardware and into oversold software leaders like Adobe (ADBE), ServiceNow (NOW), and Workday (WDAY) as they show relative strength. In the biotech space, Acadia Pharmaceuticals (ACAD) represents a high-conviction long opportunity due to an undervalued Essential Tremor drug pipeline that could generate $5 billion in revenue. Prepare for significant market volatility in the next 12 months as major AI players OpenAI and Anthropic are predicted to launch their initial public offerings (IPOs). While SpaceX maintains an aggressive $800 price target, the most immediate actionable move is covering shorts on Western Digital (WDC) and Coreweave to lock in profits following recent dips.

Investors should monitor Vera Therapeutics (VERA) ahead of its imminent FDA decision date, as positive clinical markers in kidney disease treatment could potentially double or triple the stock price. For high-risk speculative growth, Shaz (SHAZ) offers significant upside if it secures a contract with Anthropic, though it remains a "follow the smart money" play based on major insider ownership. In the software sector, HubSpot (HUBS) and Adobe (ADBE) are high-conviction picks viewed as resilient against the "SaaS apocalypse" due to their deep integration and essential tools for professional creators. While NVIDIA (NVDA) and Micron (MU) face short-term sentiment headwinds, Bloom Energy (BE) and Terawolf (WOLF) are actionable ways to play the critical energy infrastructure needs of AI data centers. Conversely, caution is advised for Capricor Therapeutics (CAPR) ahead of its July 29th FDA panel and Broadcom (AVGO), which the analyst is currently shorting due to perceived contract losses.

Investors should consider Micron (MU) as a high-conviction "buy the dip" opportunity following its recent 7-10% sell-off, which is viewed as an overreaction to broader sector volatility. Meta Platforms (META) is a strong buy for enterprise expansion as it transitions into a cloud provider, a move that could generate $10–$20 billion in new high-margin revenue. Conversely, exercise extreme caution with NVIDIA (NVDA) and specialized cloud providers like Nebius, as Meta’s entry into the chip-rental market signals a potential peak in hardware demand. For aggressive traders, SELLAS Life Sciences (SLS) is a high-conviction short or avoid, as professional short-sellers are paying a massive 150% borrow rate betting on its failure. Long-term investors seeking a "moonshot" should look toward QCLS (QC Technologies) for its 5-year potential to disrupt the industry with photonic computing that scales far beyond current GPU limits.

Investors should look to Micron Technology (MU) as a top semiconductor play, with analysts setting price targets up to $200 driven by a structural shortage in high-bandwidth memory expected to last through 2027. In the biotech sector, Abivax (ABVX) remains a high-conviction long with potential to double or quadruple if it captures its projected $5 billion to $10 billion peak sales in the immunology market. Conversely, Cerebras (CBRS) and Sellas Life Sciences (SLS) are identified as high-risk short opportunities due to poor hardware margins and skepticism regarding clinical trial data integrity. NVIDIA (NVDA) continues to be a "buy on dips" as it aggressively reinvests to maintain hardware dominance over software-based AI competitors. For broader market timing, data suggests avoiding "day trading" and instead capturing "overnight" gains, as the majority of market returns occur between the daily close and the following open.

Investors should consider Micron Technology (MU) a high-conviction "buy the dip" opportunity, as memory remains a critical, undersupplied pillar of the AI infrastructure trade. In the biotech sector, Abivax (ABVX) is a strong long play due to "best-in-disease" efficacy for its Ulcerative Colitis drug, which positions the company as a potential $5 billion acquisition target for giants like Eli Lilly. Conversely, Sellas Life Sciences (SLS) is identified as a high-conviction short, with expectations that its upcoming clinical trial will fail completely because it cannot outperform modern standard-of-care results. Rocket Lab (RKLB) is also a short candidate, as its recent acquisition news is viewed as overhyped and its current valuation is unsustainable relative to its low-margin government contract business. Finally, for those with high risk tolerance, Evomune presents a contrarian buying opportunity following a stock crash, as the market is currently assigning zero value to its promising IL-18 drug pipeline.

Investors should consider a strategic rotation out of overextended semiconductor stocks and into recovering enterprise software leaders like ServiceNow (NOW), MongoDB (MDB), and Workday (WDAY). Within the chip sector, Micron (MU) offers a compelling valuation at 10x to 13x forward earnings, though investors should trade the momentum cautiously due to potential long-term supply risks from China. In the high-growth memory space, Samsung (SSNLF) and SK Hynix (000660.KS) remain dominant plays as HBM4 supply shortages are expected to persist through the AI infrastructure build-out. For high-conviction biotech opportunities, Biohaven (BHVN) is highlighted as a top pick ahead of potential FDA approvals, while Abivax (ABVX) is positioned as a long-term winner despite recent market controversy. Avoid Capricor Therapeutics (CAPR) and Omeros (OMER), as sentiment remains bearish due to historical underperformance and fundamental concerns.

Investors should capitalize on the current "Memory Trade" momentum through Micron Technology (MU), though they must remain vigilant for a cyclical peak and potential oversupply. BioCryst Pharmaceuticals (BCRX) represents a high-conviction value play with a price target of $28, driven by the long-term potential of its rare disease pipeline. Conversely, Intel (INTC) is a prime short candidate or pair-trade laggard due to its weak AI positioning and unimpressive revenue growth compared to competitors. Avoid Sharon AI entirely, as misleading claims regarding NVIDIA (NVDA) ownership serve as a significant red flag for potential fraud. For diversified exposure to the semiconductor supercycle, maintain positions in leaders like Broadcom (AVGO) and Applied Materials (AMAT) while seeking international alpha in Japanese plays like Kioxia.

Investors should consider a long position in Meta Platforms (META), as its massive distribution and AI leadership under Alex Wang make the stock appear undervalued. Roblox (RBLX) is identified as a high-conviction growth play with "double" potential due to 40% revenue growth, though investors must monitor high stock dilution. In the biotech sector, Spruce Biosciences (SPRB) is highlighted as a speculative opportunity with 10X potential for those with a high risk tolerance. Conversely, the semiconductor sector is viewed as a "bubble," making Intel (INTC) a primary short candidate and SanDisk a high-risk, small-sized short for experienced traders. Avoid long-term exposure to Novo Nordisk (NVO) due to looming patent expirations for Ozempic, and remain cautious of Google (GOOGL) as potential disappointment in its TPU hardware could trigger a reversal.